Evaluating the Safety and Efficacy of Biologics in Oncology
American Journal Of Pharmacy And Pharmacology · 29.02.2024 · 5 (1) · 1-4
DOI: 10.71465/ajpp.3349 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal Of Pharmacy And Pharmacology, online erschienen am 29.02.2024. Verfasst von Dr. Sarah Thompson.
Abstract (Originalsprache)
Drug delivery across the blood-brain barrier (BBB) remains a significant challenge in the treatment of neurological disorders. Recent advancements in drug delivery systems (DDS) have shown promising potential in overcoming the BBB's selective permeability, enhancing the bioavailability of therapeutic agents in the brain. This article reviews the latest developments in DDS technologies such as nanoparticles, liposomes, and carrier-mediated transport systems, and evaluates their effectiveness in targeting the central nervous system (CNS). The article also discusses the current challenges, safety considerations, and future prospects for integrating DDS into clinical neurology.
Zitieren
APA
Thompson, D. S. (2024). Evaluating the Safety and Efficacy of Biologics in Oncology. American Journal Of Pharmacy And Pharmacology, 5(1), 1-4. https://doi.org/10.71465/ajpp.3349
Vancouver
Thompson DS. Evaluating the Safety and Efficacy of Biologics in Oncology. American Journal Of Pharmacy And Pharmacology. 2024;5(1):1-4. doi:10.71465/ajpp.3349
BibTeX
@article{Thompson2024,
author = {Thompson, Dr. Sarah},
title = {Evaluating the Safety and Efficacy of Biologics in Oncology},
journal = {American Journal Of Pharmacy And Pharmacology},
year = {2024},
volume = {5},
number = {1},
pages = {1--4},
doi = {10.71465/ajpp.3349}
}
EUVIMED